Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta IMM phase 2/3 trial

Autor: Hideki Fujita, Mary Flack, Atsuyuki Igarashi, Joaquin Mario Valdes, Susumu Kitamura, Mitsunori Watanabe, Mamitaro Ohtsuki, Keiko Suzaki, Xin Huang

Publikováno v: The Journal of Dermatology

Risankizumab, a humanized immunoglobulin G1 monoclonal antibody, selectively inhibits interleukin‐23, a key cytokine in the pathogenesis of psoriasis, by binding to its p19 subunit. In SustaIMM (ClinicalTrials.gov/{"type":"clinical-trial","attrs":{

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5ab30c1becacb3d1e855b2c795ccf3b
https://doi.org/10.1111/1346-8138.14941

Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis : the UltIMMa-1 and UltIMMa-2 randomized clinical trials

Autor: Joaquin Mario Valdes, Min Yang, Jo Lambert, Ziqian Geng, Elizabeth H Z Thompson, Viviana Garcia-Horton, Matthias Augustin, Avani Joshi, Eric Q. Wu, Kenneth B. Gordon, Carla Zema

Publikováno v: JAMA DERMATOLOGY
JAMA Dermatol

IMPORTANCE: Demonstrating the value of therapies from a patient’s perspective is increasingly important for patient-centered care. OBJECTIVE: To compare patient-reported outcomes (PROs) with risankizumab vs ustekinumab and placebo in psoriasis symp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abba172da5e7ff471134c361d55eba9b
https://hdl.handle.net/1854/LU-8713999

16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis

Autor: Hervé Bachelez, Brian Waterhouse, Ranjeeta Sinvhal, Andrew Blauvelt, Kristian Reich, Joaquin Mario Valdes, Mark Lebwohl, Bruce Strober, Kenneth B. Gordon, Stephanie Harbers

Publikováno v: Journal of the American Academy of Dermatology. 83:AB176

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1e9828b0a54557613860acb0bb6488fe
https://doi.org/10.1016/j.jaad.2020.06.793

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial

Autor: Yao Yu, Chih-Wei Lin, David R. Nelson, Holger Hinrichsen, Xavier Forns, Yves Horsmans, Jens Kort, Reem Ghalib, Joaquin Mario Valdes, Preethi Krishnan, Stefan Zeuzem, Federico J. Mensa, Diego Rincón, Humberto Aguilar, Samuel S. Lee, Sabela Lens, Rosa Maria Morillas, Franco Felizarta, Tarek Hassanein

Publikováno v: LANCET INFECTIOUS DISEASES
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname

Background The once-daily, ribavirin-free, pangenotypic, direct-acting antiviral regimen, glecaprevir coformulated with pibrentasvir, has shown high rates of sustained virological response in phase 2 and 3 studies. We aimed to assess the efficacy and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566e5714d52c6979c908824fb8bded5b
https://pubmed.ncbi.nlm.nih.gov/29485084

Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

Autor: Ariel Porcalla, Federico J. Mensa, Armen Asatryan, Chih-Wei Lin, Joaquin Mario Valdes, Stanley Wang, Magdy Elkhashab, Albert Tran, Tuan T. Nguyen, Edward Gane, Marcus A. Wörns, Yao Yu, Catherine A.M. Stedman, Wei Liu, Fred Poordad, Susan Greenbloom, Jean-Pierre Mulkay

Publikováno v: Gastroenterology. 152:S1089

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc5d5fc972160f3b522caf6ccdee2997
https://doi.org/10.1016/s0016-5085(17)33669-7